<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The objective of this study was to compare the clinical findings, laboratory data, functional outcome and <z:hpo ids='HP_0011010'>chronic</z:hpo> damage in male patients with <z:e sem="disease" ids="C0409980" disease_type="Disease or Syndrome" abbrv="">primary antiphospholipid syndrome</z:e> (PAPS) and <z:hpo ids='HP_0002725'>systemic lupus erythematosus</z:hpo> (SLE) </plain></SENT>
<SENT sid="1" pm="."><plain>We studied 29 male patients with PAPS and 44 with SLE </plain></SENT>
<SENT sid="2" pm="."><plain>Clinical findings, laboratory data, <z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">lupus</z:e> damage index (SLICC/ACR DI), and functional outcome in PAPS, were analysed in each group </plain></SENT>
<SENT sid="3" pm="."><plain>The mean age at diagnosis was 29.8 +/- 10.4 years in patients with PAPS and 26 +/- 10.1 years in SLE patients </plain></SENT>
<SENT sid="4" pm="."><plain>The duration of disease was 4.5 +/- 2.6 versus 5.2 +/- 3.8 years in patients with PAPS and SLE, respectively (P = NS) </plain></SENT>
<SENT sid="5" pm="."><plain>In patients with PAPS the most frequent clinical manifestations were <z:hpo ids='HP_0004936'>venous thrombosis</z:hpo>, <z:hpo ids='HP_0001873'>thrombocytopenia</z:hpo>, and pulmonary <z:hpo ids='HP_0001907'>thromboembolism</z:hpo> </plain></SENT>
<SENT sid="6" pm="."><plain>Patients with SLE had joint, skin and renal involvement more frequently than those with PAPS (P = 0.0001) </plain></SENT>
<SENT sid="7" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> PAPS patients had anticardiolipin antibodies (aCL), and 14 patients (48%) had <z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">lupus</z:e> <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> (LA) </plain></SENT>
<SENT sid="8" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> SLE patients had <z:hpo ids='HP_0003493'>antinuclear antibodies</z:hpo> (ANAs) </plain></SENT>
<SENT sid="9" pm="."><plain>Anti-dsDNA antibodies were positive in 39% of SLE patients </plain></SENT>
<SENT sid="10" pm="."><plain>Five patients died: one with 'catastrophic' APS and four with SLE </plain></SENT>
<SENT sid="11" pm="."><plain>SLICC/ACR-DI score in SLE patients was 1.9 (SD = 1) </plain></SENT>
<SENT sid="12" pm="."><plain>In PAPS patients poor functional outcome was due to <z:hpo ids='HP_0001658'>myocardial infarction</z:hpo>, pulmonary <z:hpo ids='HP_0001907'>thromboembolism</z:hpo>, <z:hpo ids='HP_0001297'>stroke</z:hpo> and mesenteric <z:mp ids='MP_0005048'>thrombosis</z:mp> </plain></SENT>
<SENT sid="13" pm="."><plain><z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">Lupus</z:e> <z:hpo ids='HP_0000123'>nephritis</z:hpo> was the principal organ damage in SLE </plain></SENT>
<SENT sid="14" pm="."><plain>In conclusion, in male patients with PAPS and SLE, the clinical manifestations were significantly different </plain></SENT>
<SENT sid="15" pm="."><plain><z:hpo ids='HP_0004420'>Arterial thrombosis</z:hpo> was the major cause of functional impairment and permanent organ damage in PAPS </plain></SENT>
<SENT sid="16" pm="."><plain>Renal involvement was the major cause of <z:hpo ids='HP_0011010'>chronic</z:hpo> damage in SLE </plain></SENT>
</text></document>